BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 31375513)

  • 21. WRN Is a Promising Synthetic Lethal Target for Cancers with Microsatellite Instability (MSI).
    Chan EM; Foster KJ; Bass AJ
    Cancer Treat Res; 2023; 186():313-328. PubMed ID: 37978143
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial.
    Sartore-Bianchi A; Trusolino L; Martino C; Bencardino K; Lonardi S; Bergamo F; Zagonel V; Leone F; Depetris I; Martinelli E; Troiani T; Ciardiello F; Racca P; Bertotti A; Siravegna G; Torri V; Amatu A; Ghezzi S; Marrapese G; Palmeri L; Valtorta E; Cassingena A; Lauricella C; Vanzulli A; Regge D; Veronese S; Comoglio PM; Bardelli A; Marsoni S; Siena S
    Lancet Oncol; 2016 Jun; 17(6):738-746. PubMed ID: 27108243
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Chemoproteomic discovery of a covalent allosteric inhibitor of WRN helicase.
    Baltgalvis KA; Lamb KN; Symons KT; Wu CC; Hoffman MA; Snead AN; Song X; Glaza T; Kikuchi S; Green JC; Rogness DC; Lam B; Rodriguez-Aguirre ME; Woody DR; Eissler CL; Rodiles S; Negron SM; Bernard SM; Tran E; Pollock J; Tabatabaei A; Contreras V; Williams HN; Pastuszka MK; Sigler JJ; Pettazzoni P; Rudolph MG; Classen M; Brugger D; Claiborne C; Plancher JM; Cuartas I; Seoane J; Burgess LE; Abraham RT; Weinstein DS; Simon GM; Patricelli MP; Kinsella TM
    Nature; 2024 May; 629(8011):435-442. PubMed ID: 38658751
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Adaptive resistance to trastuzumab impairs response to neratinib and lapatinib through deregulation of cell death mechanisms.
    Ríos-Luci C; Díaz-Rodríguez E; Gandullo-Sánchez L; Díaz-Gil L; Ocaña A; Pandiella A
    Cancer Lett; 2020 Feb; 470():161-169. PubMed ID: 31765734
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Can Microsatellite Status of Colorectal Cancer Be Reliably Assessed after Neoadjuvant Therapy?
    Goldstein JB; Wu W; Borras E; Masand G; Cuddy A; Mork ME; Bannon SA; Lynch PM; Rodriguez-Bigas M; Taggart MW; Wu J; Scheet P; Kopetz S; You YN; Vilar E
    Clin Cancer Res; 2017 Sep; 23(17):5246-5254. PubMed ID: 28522602
    [No Abstract]   [Full Text] [Related]  

  • 26. Using patient-derived xenograft models of colorectal liver metastases to predict chemosensitivity.
    Brown KM; Xue A; Julovi SM; Gill AJ; Pavlakis N; Samra JS; Smith RC; Hugh TJ
    J Surg Res; 2018 Jul; 227():158-167. PubMed ID: 29804848
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinicopathologic Characteristics of HER2-positive Metastatic Colorectal Cancer and Detection of HER2 in Plasma Circulating Tumor DNA.
    Wei Q; Zhang Y; Gao J; Li J; Li J; Li Y; Zhou J; Lu M; Gong J; Zhang X; Shen L; Sun Y; Chang L; Wang X
    Clin Colorectal Cancer; 2019 Sep; 18(3):175-182. PubMed ID: 31227437
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Microsatellite instability: a predictive marker in metastatic colorectal cancer?
    Des Guetz G; Uzzan B; Nicolas P; Schischmanoff O; Morere JF
    Target Oncol; 2009 Jan; 4(1):57-62. PubMed ID: 19343302
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The MD Anderson Prostate Cancer Patient-derived Xenograft Series (MDA PCa PDX) Captures the Molecular Landscape of Prostate Cancer and Facilitates Marker-driven Therapy Development.
    Palanisamy N; Yang J; Shepherd PDA; Li-Ning-Tapia EM; Labanca E; Manyam GC; Ravoori MK; Kundra V; Araujo JC; Efstathiou E; Pisters LL; Wan X; Wang X; Vazquez ES; Aparicio AM; Carskadon SL; Tomlins SA; Kunju LP; Chinnaiyan AM; Broom BM; Logothetis CJ; Troncoso P; Navone NM
    Clin Cancer Res; 2020 Sep; 26(18):4933-4946. PubMed ID: 32576626
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Validation of computational determination of microsatellite status using whole exome sequencing data from colorectal cancer patients.
    Johansen AFB; Kassentoft CG; Knudsen M; Laursen MB; Madsen AH; Iversen LH; Sunesen KG; Rasmussen MH; Andersen CL
    BMC Cancer; 2019 Oct; 19(1):971. PubMed ID: 31638937
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A Molecularly Annotated Model of Patient-Derived Colon Cancer Stem-Like Cells to Assess Genetic and Nongenetic Mechanisms of Resistance to Anti-EGFR Therapy.
    Luraghi P; Bigatto V; Cipriano E; Reato G; Orzan F; Sassi F; De Bacco F; Isella C; Bellomo SE; Medico E; Comoglio PM; Bertotti A; Trusolino L; Boccaccio C
    Clin Cancer Res; 2018 Feb; 24(4):807-820. PubMed ID: 28974546
    [No Abstract]   [Full Text] [Related]  

  • 32. WRN Promoter CpG Island Hypermethylation Does Not Predict More Favorable Outcomes for Patients with Metastatic Colorectal Cancer Treated with Irinotecan-Based Therapy.
    Bosch LJ; Luo Y; Lao VV; Snaebjornsson P; Trooskens G; Vlassenbroeck I; Mongera S; Tang W; Welcsh P; Herman JG; Koopman M; Nagtegaal ID; Punt CJ; van Criekinge W; Meijer GA; Monnat RJ; Carvalho B; Grady WM
    Clin Cancer Res; 2016 Sep; 22(18):4612-22. PubMed ID: 27121793
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Development of a precision medicine pipeline to identify personalized treatments for colorectal cancer.
    Altunel E; Roghani RS; Chen KY; Kim SY; McCall S; Ware KE; Shen X; Somarelli JA; Hsu DS
    BMC Cancer; 2020 Jun; 20(1):592. PubMed ID: 32580713
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Exome Sequencing of Plasma DNA Portrays the Mutation Landscape of Colorectal Cancer and Discovers Mutated VEGFR2 Receptors as Modulators of Antiangiogenic Therapies.
    Toledo RA; Garralda E; Mitsi M; Pons T; Monsech J; Vega E; Otero Á; Albarran MI; Baños N; Durán Y; Bonilla V; Sarno F; Camacho-Artacho M; Sanchez-Perez T; Perea S; Álvarez R; De Martino A; Lietha D; Blanco-Aparicio C; Cubillo A; Domínguez O; Martínez-Torrecuadrada JL; Hidalgo M
    Clin Cancer Res; 2018 Aug; 24(15):3550-3559. PubMed ID: 29588308
    [No Abstract]   [Full Text] [Related]  

  • 35. Regulator of Chromosome Condensation 2 Identifies High-Risk Patients within Both Major Phenotypes of Colorectal Cancer.
    Bruun J; Kolberg M; Ahlquist TC; Røyrvik EC; Nome T; Leithe E; Lind GE; Merok MA; Rognum TO; Bjørkøy G; Johansen T; Lindblom A; Sun XF; Svindland A; Liestøl K; Nesbakken A; Skotheim RI; Lothe RA
    Clin Cancer Res; 2015 Aug; 21(16):3759-70. PubMed ID: 25910952
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Unstable Genome and Transcriptome Dynamics during Tumor Metastasis Contribute to Therapeutic Heterogeneity in Colorectal Cancers.
    Cho SY; Chae J; Na D; Kang W; Lee A; Min S; Kang J; Choi B; Lee J; Sung CO; Chuang JH; Lee C; Lee WS; Park H; Kim JI
    Clin Cancer Res; 2019 May; 25(9):2821-2834. PubMed ID: 30670495
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A molecularly annotated platform of patient-derived xenografts ("xenopatients") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer.
    Bertotti A; Migliardi G; Galimi F; Sassi F; Torti D; Isella C; Corà D; Di Nicolantonio F; Buscarino M; Petti C; Ribero D; Russolillo N; Muratore A; Massucco P; Pisacane A; Molinaro L; Valtorta E; Sartore-Bianchi A; Risio M; Capussotti L; Gambacorta M; Siena S; Medico E; Sapino A; Marsoni S; Comoglio PM; Bardelli A; Trusolino L
    Cancer Discov; 2011 Nov; 1(6):508-23. PubMed ID: 22586653
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The Long Noncoding RNA CCAT2 Induces Chromosomal Instability Through BOP1-AURKB Signaling.
    Chen B; Dragomir MP; Fabris L; Bayraktar R; Knutsen E; Liu X; Tang C; Li Y; Shimura T; Ivkovic TC; De Los Santos MC; Anfossi S; Shimizu M; Shah MY; Ling H; Shen P; Multani AS; Pardini B; Burks JK; Katayama H; Reineke LC; Huo L; Syed M; Song S; Ferracin M; Oki E; Fromm B; Ivan C; Bhuvaneshwar K; Gusev Y; Mimori K; Menter D; Sen S; Matsuyama T; Uetake H; Vasilescu C; Kopetz S; Parker-Thornburg J; Taguchi A; Hanash SM; Girnita L; Slaby O; Goel A; Varani G; Gagea M; Li C; Ajani JA; Calin GA
    Gastroenterology; 2020 Dec; 159(6):2146-2162.e33. PubMed ID: 32805281
    [TBL] [Abstract][Full Text] [Related]  

  • 39. KHDRBS3 promotes multi-drug resistance and anchorage-independent growth in colorectal cancer.
    Ukai S; Sakamoto N; Taniyama D; Harada K; Honma R; Maruyama R; Naka K; Hinoi T; Takakura Y; Shimizu W; Ohdan H; Yasui W
    Cancer Sci; 2021 Mar; 112(3):1196-1208. PubMed ID: 33423358
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Current Microsatellite Instability Testing in Management of Colorectal Cancer.
    Sun BL
    Clin Colorectal Cancer; 2021 Mar; 20(1):e12-e20. PubMed ID: 32888812
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.